Almirall and Microsoft partner for dermatological drug development

2024-02-01
Pharmaceutical Technology
Almirall and Microsoft partner for dermatological drug development
Preview
来源: Pharmaceutical Technology
The collaboration aims to expedite the development of new dermatological treatment options. Credit: Kmpzzz / Shutterstock.com.
Pharmaceutical company Almirall has entered a strategic collaboration with Microsoft to steer innovation and digital transformation in dermatology.
The three-year collaboration will leverage generative artificial intelligence (genAI) and advanced analytics to enhance drug discovery and development processes, aiming to bring forward new treatments in medical dermatology.
Microsoft Industry Solutions, Microsoft partners and Almirall will establish a joint “digital office” which will build on the pharma company’s comprehensive data platform.
By combining Almirall’s research and development (R&D) and drug discovery capabilities with Microsoft’s digital technologies, the collaboration aims to expedite the development of new dermatological treatment options.
Almirall CEO Carlos Gallardo stated: “This agreement with Microsoft is a significant advancement in our digital transformation to achieve our goal of delivering novel treatment options for patients.
See Also:Takeda and Protagonist sign rusfertide development deal
Almirall and Microsoft partner for dermatological drug development
Preview
来源: Pharmaceutical Technology
Revolo advances plans to tackle eosinophilic esophagitis with orphan drug tag
Almirall and Microsoft partner for dermatological drug development
Preview
来源: Pharmaceutical Technology
“It will empower us to apply the latest technologies to transform our ways of working, and accelerate drug discovery.”
A significant aspect of the collaboration is the use of genAI for the quick analysis of large datasets, thereby establishing a digital, agile and patient-centric approach within Almirall’s R&D operations.
The goal is to expedite the discovery of new treatment targets and synthesisable molecules, enriching Almirall’s dermatology pipeline.
The alliance is set to streamline operations through data and AI, developing an intelligence-driven technology platform.
AI technologies will be used to select drug discovery projects, focusing on novelty and commercial potential prior to validation.
Microsoft Spain country general manager Alberto Granados stated: “Through this strategic partnership, Microsoft and its industry solutions organisation will collaborate with Almirall towards their goal of becoming the greatest dermatology company ever, revolutionising dermatological treatments and providing patients with the best possible solutions by leveraging Microsoft cutting-edge technologies of advanced analytics and generative artificial intelligence to foster innovation in drug discovery and development.”
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
机构
适应症
靶点
-
药物
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。